Low-density lipoprotein-independent effects of statins

被引:199
作者
Davignon, J
Laaksonen, R
机构
[1] Clin Res Inst Montreal, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada
[2] Univ Helsinki, Dept Clin Pharmacol, FIN-00014 Helsinki, Finland
关键词
D O I
10.1097/00041433-199912000-00010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Statins have pleiotropic properties that complement their cholesterol-lowering effects. These properties may partly account for their established benefit in the prevention of coronary artery disease beyond the reduction of LDL-cholesterol levels. The most widely recognized properties are reviewed here. They include: (i) nitric oxide-mediated improvement of endothelial dysfunction and upregulation of endothelin-1 expression; (ii) antioxidant effects; (iii) anti-inflammatory properties; (iv) inhibition of cell proliferation with anticarcinogenic actions in animals; (v) stabilization of atherosclerotic plaques; (vi) anticoagulant effects; and (vii) inhibition of graft rejection after heart and kidney transplantation. As advances are made in our knowledge, new properties are steadily being uncovered. Pleiotropic effects are currently being given consideration when instituting combination therapy for patients at high cardiovascular risk. Some pleiotropic effects are negative, and may account for occasional untoward drug interactions. For many of these new properties, the clinical relevance has not been established. The challenge for the future will be to design and carry out appropriate clinical trials to establish their relative importance in the prevention of coronary artery disease. Curr Opin Lipidol 10:543-559, (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:543 / 559
页数:17
相关论文
共 137 条
  • [1] Abetel G, 1998, SCHWEIZ MED WSCHR, V128, P272
  • [2] Aengevaeren WRM, 1997, CIRCULATION, V96, P429
  • [3] Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma - A potential mechanism of lesion stabilization
    Aikawa, M
    Rabkin, E
    Okada, Y
    Voglic, SJ
    Clinton, SK
    Brinckerhoff, CE
    Sukhova, GK
    Libby, P
    [J]. CIRCULATION, 1998, 97 (24) : 2433 - 2444
  • [4] AIKAWA M, 1998, CIRCULATION, V98, P1
  • [5] Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits
    Alegret, M
    Verd, JC
    Díaz, C
    Hernández, G
    Adzet, T
    Sánchez, RM
    Laguna, JC
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 347 (2-3) : 283 - 291
  • [6] Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis
    Alonso, DF
    Farina, HG
    Skilton, G
    Gabri, MR
    De Lorenzo, MS
    Gomez, DE
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 50 (01) : 83 - 93
  • [7] Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin
    Alvarez, JM
    Rawdanowiz, TJ
    Goldstein, J
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1998, 116 (04) : 654 - 655
  • [8] THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION
    ANDERSON, TJ
    MEREDITH, IT
    YEUNG, AC
    FREI, B
    SELWYN, AP
    GANZ, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) : 488 - 493
  • [9] Andrews TC, 1997, CIRCULATION, V95, P324
  • [10] Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
    Aviram, M
    Rosenblat, M
    Bisgaier, CL
    Newton, RS
    [J]. ATHEROSCLEROSIS, 1998, 138 (02) : 271 - 280